Expression system for expressing herpesvirus glycoprotein complexes

Patent metadata

Field	Value
Publication number	US-11844833-B2
Application number	US-202217806157-A
Country	US
Kind code	B2
Filing date	Jun 9, 2022
Priority date	Jul 13, 2017
Publication date	Dec 19, 2023
Grant date	Dec 19, 2023

Abstract

An expression system for expressing a herpesvirus glycoprotein complex including a vector inserted with two or more nucleic acid sequences that encode two or more subunits of a herpesvirus glycoprotein complex linked by one or more linking sequences such that the subunits are co-expressed simultaneously and self-processed to assemble into a glycoprotein complex. The expression system or the vector can be included in a vaccine composition. The vaccine composition can be used for preventing or treating herpesvirus infections.

First claim

What is claimed is:

1. A pharmaceutical composition comprising:
(i) one or more vectors, each vector comprising one or more expression cassette(s), each expression cassette comprising:
a single promoter;
two or more nucleic acid sequences that encode two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof, wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof, when expressed by the expression cassette, form a herpesvirus glycoprotein complex that is functional and effectively elicits neutralizing antibody responses, and wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof are derived from varicella-zoster virus (VZV), Epstein-Barr virus (EBV), Kaposi's Sarcoma-associated herpesvirus (KSHV), human herpesvirus 6 (HHV-6), human herpesvirus 7 (HHV-7);
one or more 2A peptide signal sequences that mediate ribosomal skipping or one or more internal ribosomal entry sites between each of the two or more nucleic acid sequences;
wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof are simultaneously expressed by the expression cassette;
wherein the one or more vectors is (i) a plasmid or (ii) a viral vector selected from a CMV vector, a vaccinia vector, or an adenoviral vector; and

(ii) a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof.

2. The pharmaceutical composition of claim 1 , wherein each vector further comprises a second expression cassette comprising:
a second promoter;
two or more nucleic acid sequences that encode two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof, wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof, when expressed by the expression system, form a herpesvirus glycoprotein complex;
one or more 2A signal sequences between each of the two or more nucleic acid sequences;
wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof of the first expression cassette and the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof of the second expression cassette are simultaneously expressed by the expression system; and
wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof of each expression cassette are derived from varicella-zoster virus (VZV), Epstein-Barr virus (EBV), Kaposi's Sarcoma-associated herpesvirus (KSHV), human herpesvirus 6 (HHV-6), human herpesvirus 7 (HHV-7).

3. The pharmaceutical composition of claim 1 , wherein the one or more 2A signal sequence encode a 2A peptide of foot-and-mouth disease virus (F2A), a 2A peptide of equine rhinitis A virus (E2A), a 2A peptide of porcine teschovirus-1 (P2A), a 2A peptide of cytoplasmic polyhedrosis virus (BmCPV 2A), a 2A peptide of flacherie virus (BmIFV 2A), or a 2A peptide of Thosea asigna virus (T2A).

4. The pharmaceutical composition of claim 1 , wherein the expression cassette further comprises a furin cleavage site upstream of each of the one or more 2A signal sequences.

5. The pharmaceutical composition of claim 1 , wherein the promoter is a single promoter sequence located upstream of the subunits or the antigenic fragments thereof.

6. The pharmaceutical composition of claim 1 , wherein the promoter is a vaccinia virus mH5 promoter, a pSyn promoter, a p7.5 promoter, or a p11 promoter.

7. The pharmaceutical composition of claim 1 , wherein the two or more herpesvirus glycoprotein complex subunits include gD of HSV, gp350/220 of EBV, gpK8.1 of KSHV.

8. The pharmaceutical composition of claim 1 , wherein the nucleic acid sequence encodes EBV EBNA1 or LMP2, or KSHV LANA, or other immunodominant antigens.

9. The pharmaceutical composition of claim 1 , wherein the two or more nucleic acid sequences are naturally occurring DNA sequences.

10. The pharmaceutical composition of claim 1 , wherein the two or more nucleic acid sequences are codon-optimized.

11. The pharmaceutical composition of claim 1 , wherein the two or more nucleic acid sequences are DNA sequences.

12. The pharmaceutical composition of claim 1 , wherein the vector is a modified vaccinia Ankara (MVA) vector.

13. A pharmaceutical composition comprising:
(i) a first vector comprising a first expression cassette, the first expression cassette comprising:
a first promoter, two or more nucleic acid sequences that encode two or more amino acids herpesvirus glycoprotein complex subunits or antigenic fragments thereof, and
one or more 2A signal sequences between each of the two or more nucleic acid sequences,
wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof, when expressed by the first expression cassette, form a herpesvirus glycoprotein complex;
wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof are derived from varicella-zoster virus (VZV), Epstein-Barr virus (EBV), Kaposi's Sarcoma-associated herpesvirus (KSHV), human herpesvirus 6 (HHV-6), human herpesvirus 7 (HHV-7); and
wherein the first vector is (i) a plasmid or (ii) a viral vector selected from a CMV vector, a vaccinia vector, or an adenoviral vector; and

(ii) a second vector comprising a second expression cassette, the second expression cassette comprising:
a second promoter, two or more nucleic acid sequences that encode two or more amino acids herpesvirus glycoprotein complex subunits or antigenic fragments thereof, and
one or more 2A signal sequences between each of the two or more nucleic acid sequences, wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof, when expressed by the second expression cassette, form a herpesvirus glycoprotein complex;
wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof are derived from varicella-zoster virus (VZV), Epstein-Barr virus (EBV), Kaposi's Sarcoma-associated herpesvirus (KSHV), human herpesvirus 6 (HHV-6), human herpesvirus 7 (HHV-7); and
wherein the second vector is (i) a plasmid or (ii) a viral vector selected from a CMV vector, a vaccinia vector, or an adenoviral vector;
wherein the two or more herpesvirus glycoprotein complex subunits or antigenic fragments thereof of the first and second vectors are simultaneously expressed; and

(iii) a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof.

14. The pharmaceutical composition of claim 13 , wherein the one or more 2A signal sequence encode a 2A peptide of foot-and-mouth disease virus (F2A), a 2A peptide of equine rhinitis A virus (E2A), a 2A peptide of porcine teschovirus-1 (P2A), a 2A peptide of cytoplasmic polyhedrosis virus (BmCPV 2A), a 2A peptide of flacherie virus (BmIFV 2A), or a 2A peptide of Thosea asigna virus (T2A).

15. The pharmaceutical composition of claim 13 , wherein the expression cassette further comprises a furin cleavage site upstream of each of the one or more 2A signal sequences.

16. The pharmaceutical composition of claim 13 , wherein the first promotor and/or the second promoter is a single promoter sequence located upstream of the subunits or the antigenic fragments thereof.

17. The pharmaceutical composition of claim 13 , wherein the promoter is a vaccinia virus mH5 promoter, a pSyn promoter, a p7.5 promoter, or a p11 promoter.

18. The pharmaceutical composition of claim 13 , wherein the two or more herpesvirus glycoprotein complex subunits include gD of

Assignees

• Hope City

Inventors

• Wussow Felix
• Diamond Don J

Classifications

• A61K39/245 Primary

  Herpetoviridae, e.g. herpes simplex virus · CPC title

• C07K14/045

  Cytomegalovirus · CPC title

• C07K14/05

  Epstein-Barr virus · CPC title

• C07K14/005 Primary

  from viruses · CPC title

• A61K39/12

  Viral antigens · CPC title